Page last updated: 2024-08-23

selegiline and Parkinson Disease, Secondary

selegiline has been researched along with Parkinson Disease, Secondary in 52 studies

Research

Studies (52)

Timeframe	Studies, this research(%)	All Research%
pre-1990	19 (36.54)	18.7374
1990's	27 (51.92)	18.2507
2000's	4 (7.69)	29.6817
2010's	1 (1.92)	24.3611
2020's	1 (1.92)	2.80

Authors

Authors	Studies
Chen, KZ; Hao, GF; Jin, CF; Wang, ZZ; Xu, TF	1
Bajaj, A; Gaud, R; Meshram, P; Sridhar, V; Wairkar, S	1
Inoue, H; Taguchi, Y; Takashima, S	1
Arató, M; Bagdy, G; Perényi, A	1
Bergmann, KJ; Mendoza, MR; Moros, D; Yahr, MD	1
Williams, A	1
Cohen, B; Cohen, G; Leist, A; Mytilineou, C; Pasik, P; Yahr, MD	1
Csanaky, A; Gyimóti, G; Leposa, D	1
Antóny, M; Széplaki, Z; Tóth, G	1
Cadet, JL; Gewirtz, GR; Gorman, JM; Sarti, P; Sharif, Z	1
Tipton, KF	1
Adeyemo, OM; Markey, CJ; Markey, SP; Pollard, HB; Youdim, MB	1
Tatton, WG	1
Rinne, JO	1
LeWitt, PA; Mistura, KL; Schork, MA; Segel, SA	1
Arányi, P; Gaál, J; Kardos, V; Király, I; Kollár, E; Patthy, M; Sziráki, I; Tömösközi, Z	1
Olanow, CW	1
Kuhn, W; Müller, T	1
Koller, WC	1
Hirobe, M; Kotake, Y; Ohta, S; Tasaki, Y	1
Bernardi, G; Bonci, A; Federici, M; Mercuri, NB; Scarponi, M; Siniscalchi, A	1
Ahlskog, JE	2
Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM	1
Barja, G; Fabre, E; Gredilla, R; Leret, ML; San Millán, JA	1
Tipton, KF; Youdim, MB	1
Johnson, SK; Medina, D; Wagner, GC	1
Hermecz, I; Szatmári, I	1
Langston, JW; Tetrud, JW	3
Lieberman, A	1
Greenwood, CE; Tatton, WG	1
Chan, WW; Rausch, WD; Riederer, P; Schallauer, E; Weiser, M	1
Chen, S	1
Boulton, AA; Juorio, AV; Paterson, IA	1
Baas, H; Fischer, PA	1
Teräväinen, H	1
Langston, JW	2
Bradbury, AJ; Costall, B; Jenner, PG; Kelly, ME; Marsden, CD; Naylor, RJ	1
Lewin, R	2
Hashim, A; Lajtha, A; Sershen, H; Wiener, HL	1
Akos, K	1
Bonetti, EP; Da Prada, M; Imhof, R; Keller, HH; Kettler, R	1
Bustos, JC; de Yebenes, JG; Fahn, S; Jackson-Lewis, V; Jorge, P; Lovelle, S; Magariños, C; Martinez, A; Mena, MA; Reiriz, J	1
Jenner, P; Marsden, CD	1
Sandler, M	1
Finberg, JP; Youdim, MB	1

Reviews

12 review(s) available for selegiline and Parkinson Disease, Secondary

Article	Year
What is it that l-deprenyl (selegiline) might do? Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:6 Pt 2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Monoamine Oxidase Inhibitors; Nervous System; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1994
Selegiline can mediate neuronal rescue rather than neuronal protection. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8 Suppl 1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Isoenzymes; Mice; Mice, Inbred BALB C; Monoamine Oxidase; Motor Neurons; Nerve Degeneration; Parkinson Disease, Secondary; Selegiline; Substantia Nigra	1993
Nigral degeneration in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8 Suppl 1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Haplorhini; Humans; Isoenzymes; Monoamine Oxidase; Nerve Degeneration; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Selegiline; Substantia Nigra	1993
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. Journal of neural transmission. Supplementum, 1996, Volume: 48 Topics: 1-Methyl-4-phenylpyridinium; Antioxidants; Apoptosis; Clinical Trials as Topic; Dopamine; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline	1996
The clinical potential of Deprenyl in neurologic and psychiatric disorders. Journal of neural transmission. Supplementum, 1996, Volume: 48 Topics: Adult; Aged; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Antipsychotic Agents; Child; Clinical Trials as Topic; Cross-Over Studies; Depression; Double-Blind Method; Humans; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Narcolepsy; Nervous System Diseases; Neuroprotective Agents; Nootropic Agents; Parkinson Disease, Secondary; Schizophrenia; Selegiline; Supranuclear Palsy, Progressive; Tourette Syndrome; Treatment Outcome	1996
Neuroprotective therapy for Parkinson's disease. Experimental neurology, 1997, Volume: 144, Issue:1 Topics: Animals; Antiparkinson Agents; Humans; Infections; Mitochondria; MPTP Poisoning; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1997
Medical treatment of later-stage motor problems of Parkinson disease. Mayo Clinic proceedings, 1999, Volume: 74, Issue:12 Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone	1999
Protective and preventive therapeutic strategies: monoamine oxidase inhibitors. Neurologic clinics, 1992, Volume: 10, Issue:2 Topics: Humans; Monoamine Oxidase Inhibitors; MPTP Poisoning; Parkinson Disease; Parkinson Disease, Secondary; Selegiline; Substantia Nigra	1992
[Slowing the progression of Parkinson syndrome by early administration of deprenyl]. Der Nervenarzt, 1990, Volume: 61, Issue:2 Topics: Animals; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Selegiline	1990
Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology, 1990, Volume: 40, Issue:10 Suppl 3 Topics: Brain; Free Radicals; Humans; Models, Neurological; Monoamine Oxidase; Neurotoxins; Oxygen; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1990
Parkinson's disease: new treatment strategies. Comprehensive therapy, 1990, Volume: 16, Issue:12 Topics: Adrenal Medulla; Animals; Brain Tissue Transplantation; Fetal Tissue Transplantation; Humans; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1990
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Journal of neural transmission. Supplementum, 1986, Volume: 20 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra	1986

Trials

9 trial(s) available for selegiline and Parkinson Disease, Secondary

Article	Year
Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. Clinical neuropharmacology, 1993, Volume: 16, Issue:4 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Picolinic Acids; Selegiline	1993
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Annals of neurology, 1996, Volume: 39, Issue:1 Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E	1996
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Annals of neurology, 1996, Volume: 39, Issue:1 Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E	1996
Selegiline in Parkinson's disease. Acta neurologica Scandinavica, 1990, Volume: 81, Issue:4 Topics: Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Phenethylamines; Random Allocation; Selegiline	1990
Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology, 1990, Volume: 40, Issue:10 Suppl 3 Topics: Brain; Free Radicals; Humans; Models, Neurological; Monoamine Oxidase; Neurotoxins; Oxygen; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1990
Big first scored with nerve diseases. Science (New York, N.Y.), 1989, Aug-04, Volume: 245, Issue:4917 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Designer Drugs; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline; Substantia Nigra	1989
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science (New York, N.Y.), 1989, Aug-04, Volume: 245, Issue:4917 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Random Allocation; Selegiline	1989
R-(-)-deprenyl as a possible protective agent in Parkinson's disease. Journal of neural transmission. Supplementum, 1987, Volume: 25 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Models, Theoretical; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline	1987
Clinical trial for Parkinson's disease? Science (New York, N.Y.), 1985, Nov-01, Volume: 230, Issue:4725 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Levodopa; Models, Neurological; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Pyridines; Pyridinium Compounds; Selegiline	1985

Other Studies

32 other study(ies) available for selegiline and Parkinson Disease, Secondary

Article	Year
Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor. Journal of medicinal chemistry, 2020, 12-10, Volume: 63, Issue:23 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Amides; Animals; Benzylamines; Binding Sites; Dopaminergic Neurons; Drug Design; Humans; Male; Mice, Inbred ICR; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Protein Binding; Structure-Activity Relationship	2020
Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease. Journal of drug targeting, 2018, Volume: 26, Issue:2 Topics: Adhesiveness; Administration, Intranasal; Animals; Biological Availability; Brain; Drug Delivery Systems; Gels; Humans; Male; Nasal Mucosa; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone; Selegiline	2018
[A case of interval form of carbon monoxide poisoning with a remarkable recovery]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2005, Volume: 42, Issue:3 Topics: Acute Disease; Aged; Antiparkinson Agents; Brain; Carbon Monoxide Poisoning; Cytidine Diphosphate Choline; Drug Therapy, Combination; Female; Humans; Hyperbaric Oxygenation; Levodopa; Parkinson Disease, Secondary; Selegiline	2005
An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced parkinsonism. Pharmacopsychiatria, 1983, Volume: 16, Issue:5 Topics: Adult; Antipsychotic Agents; Drug Evaluation; Female; Humans; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease, Secondary; Phenethylamines; Prolactin; Schizophrenia; Selegiline	1983
Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline). Acta neurologica Scandinavica. Supplementum, 1983, Volume: 95 Topics: Drug Therapy, Combination; Humans; Levodopa; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Time Factors	1983
MPTP parkinsonism. British medical journal (Clinical research ed.), 1984, Nov-24, Volume: 289, Issue:6456 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Humans; Male; Mice; Parkinson Disease, Secondary; Pyridines; Saimiri; Selegiline; Substance-Related Disorders	1984
Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. European journal of pharmacology, 1984, Oct-30, Volume: 106, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Dopamine; Female; Homovanillic Acid; Macaca fascicularis; Pargyline; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline	1984
Observations made with L-deprenil (Jumex) in the long-term treatment of outpatients with Parkinson's syndrome. Therapia Hungarica (English edition), 1983, Volume: 31, Issue:1 Topics: Aged; Ambulatory Care; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Statistics as Topic; Time Factors	1983
Clinicopharmacological study of long-term Jumex + Dopaflex combination treatment in Parkinson's syndrome. Therapia Hungarica (English edition), 1982, Volume: 30, Issue:4 Topics: Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Time Factors	1982
Selegiline for neuroleptic-induced parkinsonism. Pharmacopsychiatry, 1993, Volume: 26, Issue:4 Topics: Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Schizophrenia; Selegiline	1993
L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish. European journal of pharmacology, 1993, Aug-24, Volume: 240, Issue:2-3 Topics: Animals; Brain; Clorgyline; Disease Models, Animal; Dopamine; Goldfish; Monoamine Oxidase; Motor Activity; MPTP Poisoning; Norepinephrine; Parkinson Disease, Secondary; Selegiline	1993
Novel sites of action for deprenyl in MPTP-parkinsonism: metabolite-mediated protection against striatal neurotoxicity and suppression of MPTP-induced increase of dopamine turnover in C57BL mice. Progress in brain research, 1995, Volume: 106 Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Parkinson Disease; Parkinson Disease, Secondary; Selegiline; Time Factors	1995
Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline in mice: in vivo and in vitro studies. Brain research, 1998, Mar-23, Volume: 787, Issue:2 Topics: Animals; Anti-Arrhythmia Agents; Brain Chemistry; Chromatography, Gas; Depression, Chemical; In Vitro Techniques; Isoquinolines; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Tetrahydroisoquinolines	1998
Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease. Annals of neurology, 1998, Volume: 43, Issue:5 Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Electrophysiology; Injections, Intraperitoneal; Levodopa; Male; Membrane Potentials; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Wistar; Selegiline	1998
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome. Neurobiology of disease, 2001, Volume: 8, Issue:3 Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Electromyography; Female; Genes, Recessive; Immunohistochemistry; Indoles; Levodopa; Male; Memory Disorders; Mice; Mice, Inbred C3H; Mice, Neurologic Mutants; Motor Activity; Neurons; Parkinson Disease, Secondary; Postural Balance; Selegiline; Tyrosine 3-Monooxygenase	2001
Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum. Toxicology, 2002, Jan-25, Volume: 170, Issue:3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Catecholamines; Dopamine; Dopamine Agents; Glutathione; Male; Neostriatum; Oxidation-Reduction; Parkinson Disease, Secondary; Rats; Rats, Wistar; Selegiline; Stereotaxic Techniques	2002
Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Parkinsonism & related disorders, 2002, Volume: 8, Issue:4 Topics: Animals; Behavior, Animal; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism; Indans; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Phenethylamines; Psychotropic Drugs; Rats; Rats, Sprague-Dawley; Selegiline; Stereotyped Behavior	2002
The effects of deprenyl on methamphetamine-induced dopamine depletions. Journal of neural transmission. General section, 1992, Volume: 89, Issue:1-2 Topics: Animals; Corpus Striatum; Dopamine; Male; Methamphetamine; Mice; Parkinson Disease, Secondary; Selegiline; Serotonin	1992
[Positron emission tomography of C-11-labelled selegiline]. Acta pharmaceutica Hungarica, 1992, Volume: 62, Issue:5 Topics: Animals; Brain; Carbon Radioisotopes; Male; Mice; Monoamine Oxidase; Parkinson Disease, Secondary; Selegiline; Tomography, Emission-Computed	1992
Emerging perspectives in Parkinson's disease. Neurology, 1992, Volume: 42, Issue:4 Suppl 4 Topics: Animals; Humans; Levodopa; MPTP Poisoning; Neurology; Parkinson Disease; Parkinson Disease, Secondary; Selegiline	1992
Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. Journal of neuroscience research, 1991, Volume: 30, Issue:4 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Cell Survival; Mice; Mice, Inbred C57BL; Neurons; Parkinson Disease, Secondary; Selegiline; Sodium Chloride; Substantia Nigra; Tyrosine 3-Monooxygenase	1991
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism. Journal of neural transmission. Supplementum, 1990, Volume: 32 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Interactions; Female; Gerbillinae; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Parkinson Disease, Secondary; Selegiline; Serotonin	1990
[Study of an MPTP-induced parkinsonian animal model in the rhesus monkey and the mechanism of the action of MPTP]. Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry, 1990, Volume: 23, Issue:1 Topics: Animals; Disease Models, Animal; Macaca mulatta; Male; MPTP Poisoning; MSH Release-Inhibiting Hormone; Parkinson Disease, Secondary; Selegiline	1990
Possible mechanism of action of deprenyl in parkinsonism. Lancet (London, England), 1990, Jul-21, Volume: 336, Issue:8708 Topics: Animals; Dopamine; Parkinson Disease, Secondary; Phenethylamines; Rats; Rats, Inbred Strains; Selegiline; Stimulation, Chemical	1990
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment. Neuroscience letters, 1985, Jul-31, Volume: 58, Issue:2 Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Female; Homovanillic Acid; Hydroxyindoleacetic Acid; Limbic System; Mice; Motor Activity; Neurotransmitter Agents; Norepinephrine; Parkinson Disease, Secondary; Phenethylamines; Pyridinium Compounds; Selegiline; Serotonin	1985
Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice. Journal of neuroscience research, 1989, Volume: 23, Issue:3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Male; Mice; Mice, Inbred BALB C; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline; Time Factors	1989
MPTP, selegiline, and parkinsonism. Lancet (London, England), 1987, Jan-03, Volume: 1, Issue:8523 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline	1987
Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. Advances in neurology, 1987, Volume: 45 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzamides; Brain; Corpus Striatum; Dopamine; Male; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Parkinson Disease, Secondary; Pyridines; Rats; Selegiline; Substantia Nigra; Tyramine	1987
Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:3 Topics: Animals; Brain; Corpus Striatum; Dopamine; Dopamine Agents; Infusion Pumps; Injections, Intraventricular; Lisuride; Macaca fascicularis; Male; Neural Pathways; Parkinson Disease, Secondary; Pergolide; Rats; Receptors, Dopamine; Selegiline; Stereotyped Behavior; Substantia Nigra	1987
(-)Deprenyl in perspective: prophylaxis for Parkinson's disease? Journal of neural transmission. Supplementum, 1986, Volume: 22 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Arylsulfotransferase; Blood Platelets; Humans; Monoamine Oxidase; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline; Sulfurtransferases; Tomography, Emission-Computed	1986
MAO type B inhibitors as adjunct to L-dopa therapy. Advances in neurology, 1987, Volume: 45 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine	1987
Parkinson's disease: current view. American family physician, 1987, Volume: 35, Issue:3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Selegiline; Substantia Nigra; Tomography, Emission-Computed	1987